Statement from Dee Stewart, President of Americans for a Balanced Budget, on CMS’ Final Rule for the Medicare Drug Price Negotiation Program for 2029

Statement from Dee Stewart, President of Americans for a Balanced Budget, on CMS’ Final Rule for the Medicare Drug Price Negotiation Program for 2029

“We are disappointed with the Centers for Medicare & Medicaid Services (CMS) for finalizing the rule for the next round of the Medicare Drug Price Negotiation Program. By finalizing the fixed-dose combination provision, CMS risks creating additional barriers to the development of innovative treatments, particularly for cancer patients who depend on continued medical breakthroughs.

“Fixed-dose combination therapies play an important role in advancing medical innovation, particularly in cancer treatment, by turning multi-dose regimens into single-dose treatments. By finalizing this rule, CMS risks discouraging investment in new and improved therapies by reducing the incentives for innovation with price controls. This is especially concerning for cancer patients in rural and underserved communities, who already face significant barriers to accessing specialized care and could benefit from more convenient treatment options. Rather than encouraging the next generation of medical breakthroughs, these regulations risk limiting the very innovations patients need most.

“Lawmakers must recognize that decisions intended to lower healthcare costs should not come at the expense of patient access and future medical innovation. We are disappointed that CMS failed to adequately address these concerns in the final rule. Patients deserve policies that both improve affordability and encourage the development of lifesaving treatments, not regulations that risk standing in the way of the next generation of cancer breakthroughs.”